Financial Counselors Inc. trimmed its position in GRIFOLS S A/S (NASDAQ:GRFS) by 6.6% in the 1st quarter, HoldingsChannel.com reports. The firm owned 12,958 shares of the biotechnology company’s stock after selling 919 shares during the quarter. Financial Counselors Inc.’s holdings in GRIFOLS S A/S were worth $261,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in GRFS. AKO Capital LLP lifted its holdings in shares of GRIFOLS S A/S by 24.7% during the 4th quarter. AKO Capital LLP now owns 12,283,473 shares of the biotechnology company’s stock worth $225,525,000 after acquiring an additional 2,436,502 shares during the last quarter. Two Sigma Advisers LP lifted its holdings in shares of GRIFOLS S A/S by 502.7% during the 4th quarter. Two Sigma Advisers LP now owns 134,400 shares of the biotechnology company’s stock worth $2,468,000 after acquiring an additional 112,100 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of GRIFOLS S A/S by 1.2% during the 4th quarter. Bank of America Corp DE now owns 1,443,713 shares of the biotechnology company’s stock worth $26,506,000 after acquiring an additional 16,818 shares during the last quarter. CIBC Asset Management Inc lifted its holdings in shares of GRIFOLS S A/S by 79.6% during the 1st quarter. CIBC Asset Management Inc now owns 210,981 shares of the biotechnology company’s stock worth $4,243,000 after acquiring an additional 93,510 shares during the last quarter. Finally, Todd Asset Management LLC lifted its holdings in shares of GRIFOLS S A/S by 3.1% during the 1st quarter. Todd Asset Management LLC now owns 879,670 shares of the biotechnology company’s stock worth $17,690,000 after acquiring an additional 26,467 shares during the last quarter. 19.02% of the stock is owned by hedge funds and other institutional investors.

GRIFOLS S A/S stock opened at $17.59 on Monday. The company has a quick ratio of 1.13, a current ratio of 2.87 and a debt-to-equity ratio of 1.41. The firm has a market capitalization of $12.09 billion, a price-to-earnings ratio of 15.03, a price-to-earnings-growth ratio of 1.25 and a beta of 1.03. GRIFOLS S A/S has a twelve month low of $17.42 and a twelve month high of $24.97.

GRIFOLS S A/S (NASDAQ:GRFS) last posted its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported $0.25 earnings per share for the quarter, hitting the consensus estimate of $0.25. The business had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. GRIFOLS S A/S had a net margin of 12.35% and a return on equity of 15.49%. On average, equities analysts anticipate that GRIFOLS S A/S will post 1.29 EPS for the current fiscal year.

The firm also recently declared a dividend, which will be paid on Tuesday, June 18th. Shareholders of record on Monday, June 10th will be paid a $0.14 dividend. The ex-dividend date is Friday, June 7th. GRIFOLS S A/S’s dividend payout ratio is presently 29.91%.

A number of analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of GRIFOLS S A/S from a “hold” rating to a “sell” rating in a report on Monday, April 1st. BidaskClub downgraded shares of GRIFOLS S A/S from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 16th. Finally, Berenberg Bank downgraded shares of GRIFOLS S A/S from a “buy” rating to a “hold” rating in a research note on Friday, February 8th. Three analysts have rated the stock with a sell rating and four have given a hold rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $19.00.

ILLEGAL ACTIVITY NOTICE: “Financial Counselors Inc. Has $261,000 Holdings in GRIFOLS S A/S (GRFS)” was reported by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.watchlistnews.com/financial-counselors-inc-has-261000-holdings-in-grifols-s-a-s-grfs/3030157.html.

About GRIFOLS S A/S

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.

Recommended Story: Fundamental Analysis

Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GRIFOLS S A/S (NASDAQ:GRFS).

Institutional Ownership by Quarter for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.